Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (341)	11/19/1999 10:29:00 AM
From: Skywatcher	Respond to of 1137

SciClone Appoints Two New Regional Managing Directors to Expand ZADAXIN(R) Sales in Latin America and the Middle East Mexico Launch Planned SAN MATEO, Calif., Nov. 19 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) announced the appointment of Craig R. Olson as Regional Managing Director, Latin America and Kenneth R. Cowan as Regional Managing Director, Middle East for the Company's international subsidiary, SciClone Pharmaceuticals International, Ltd. Olson and Cowan become SciClone's first dedicated regional executives in Latin America and the Middle East, respectively. SciClone said one of Olson's primary responsibilities will be to manage the near term launch of ZADAXIN, the Company's immune system enhancer for cancer, hepatitis B and hepatitis C, in Mexico. Olson is a 19-year veteran of Schering-Plough Corporation in Latin America, most recently as a general manager. He earned his Masters in International Business from the University of South Carolina, his B.S. in Business Administration from the University of Montana and speaks Spanish and Portuguese fluently. Cowen also has 19 years of marketing experience, including positions at Merck, Sterling International and Sanofi Winthrop, and earned his Masters in Business Administration and his A.B. in Philosophy from Columbia University. ''Latin America and the Middle East will play a significantly expanded role in our move toward profitable operations next year, and Craig and Ken are the perfect men for the job,'' said Donald R. Sellers, SciClone's president and chief executive officer. ''After helping to establish alpha interferon as the region's dominant hepatitis treatment, we have every confidence in Craig's ability to position SciClone's ZADAXIN as a safer alternative and more effective combination therapy. Ken's experience and local contacts in the key markets in the Middle East, Turkey, Egypt and Saudi Arabia, will enable him to expand our ZADAXIN sales in this important region.'' SciClone's ZADAXIN boosts the body's immune system, without any serious side effects, in the fight against life-threatening diseases such as hepatitis B, hepatitis C, HIV/AIDS and cancer. ZADAXIN currently is approved for sale in Mexico, Argentina, Venezuela and Peru. Additionally, ZADAXIN is approved in Italy and 12 additional countries throughout Asia and the Middle East. SciClone recently announced its seventh consecutive quarter of ZADAXIN sales growth in excess of 20 percent, principally from China, where Sellers said the Company should benefit from the recent market-opening pact between the U.S. and China. Sellers also said he expects ZADAXIN sales in Latin America and the Middle East to contribute importantly to the Company's sales growth beginning in the first quarter of 2000 THIS IS GREAT NEWS! This guy sounds like JUST THE TICKET... chris